Connect Sign In
Autoimmune Movement Disorder Panel, Serum
Ordering Recommendation
Use to evaluate subacute-onset movement disorders. If new-onset epilepsy is the prominent feature, refer to Autoimmune Epilepsy Panel, Serum (3006204). If there are subacute-onset neurologic symptoms in the absence of movement disorders, refer to Autoimmune Encephalopathy/Dementia Panel, Serum (3006201). For testing in individuals <18 years of age, refer to Autoimmune Pediatric CNS Disorders, Serum (3006210).
Testing in both serum and CSF is recommended to maximize diagnostic yield; refer to Autoimmune Movement Disorder Panel, CSF (3006207) for CSF testing.
New York DOH Approval Status
Specimen Required
Serum separator tube (SST)
Separate from cells ASAP or within 2 hours of collection. Transfer three 1 mL serum aliquots to ARUP standard transport tubes. (Min: 0.5 mL/aliquot)
Frozen
Amniotic fluid, ocular fluid, peritoneal fluid, synovial fluid, CSF, or plasma. Contaminated, hemolyzed, icteric, or lipemic specimens.
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 month (avoid repeated freeze/thaw cycles)
Methodology
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody/Semi-Quantitative Indirect Fluorescent Antibody (IFA)/Qualitative Immunoblot/Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)/Quantitative Radioimmunoassay (RIA)
Performed
Varies
Reported
3-10 days
Reference Interval
| Test Number |
Components |
Reference Interval |
|---|---|---|
| CV2 Ab IgG CBA-IFA Screen, Serum | Less than 1:100 | |
| Neuronal Antibody (Amphiphysin) | Negative | |
| Glutamic Acid Decarboxylase Antibody | 0.0-5.0 IU/mL | |
| Purkinje Cell/Neuronal Nuclear IgG Scrn | None Detected | |
| NMDA Receptor Ab IgG CBA-IFA, Serum | Less than 1:10 | |
| P/Q-Type Calcium Channel Antibody | 24.5 pmol/L or less | |
| SOX1 Antibody, IgG by Immunoblot, Serum | Negative | |
| AMPA Receptor Ab IgG CBA-IFA Scrn, Serum | Less than 1:10 | |
| GABA-BR Ab IgG CBA-IFA Scrn, Ser | Less than 1:10 | |
| DPPX Ab IgG CBA-IFA Screen, Serum | Less than 1:10 | |
| GABA-AR Ab IgG CBA-IFA Screen, Serum | Less than 1:10 | |
| IgLON5 Ab IgG CBA-IFA Screen, Serum | Less than 1:10 | |
| mGluR1 Ab IgG CBA-IFA Screen, Serum | Less than 1:10 | |
| ITPR1 Ab IgG CBA-IFA Screen, Serum | Less than 1:10 | |
| CASPR2 Ab IgG CBA-IFA Screen, Serum | Less than 1:10 | |
| LGI1 Ab IgG CBA-IFA Screen, Serum | Less than 1:10 |
Interpretive Data
Refer to report.
| Component | Interpretation |
|---|---|
| P/Q-Type Voltage-Gated Calcium Channel (VGCC) Antibody | 0.0-24.5 pmol/L Negative 24.6-45.6 pmol/L Indeterminate 45.7 pmol/L or greater Positive |
Laboratory Developed Test (LDT)
Note
If NMDA antibody IgG is positive, then titer will be performed. Additional charges apply.
If CV2 antibody IgG is positive, then titer will be added. Additional charges apply.
PCCA/ANNA antibody IgG is screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri, Yo, and Tr/DNER) IgG by Immunoblot will be performed. If the IFA screen is positive at 1:10 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be performed. Additional charges apply.
If LGI1 antibody IgG is positive, then titer will be added. Additional charges apply.
If CASPR2 antibody IgG is positive, then titer will be added. Additional charges apply.
If DPPX antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
If AMPA antibody IgG is positive, then titer will be added. Additional charges apply.
If GABA-BR antibody IgG is positive, then titer will be added. Additional charges apply.
If GABA-AR antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
If mGluR1 antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
If ITPR1 antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
If IgLON5 antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
Hotline History
Hotline History
CPT Codes
86341; 86596; 84182 x2; 86255 x12; if reflexed add 84182 x4; 86256 per titer
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0051709 | Neuronal Antibody (Amphiphysin) | 94385-2 |
| 0092629 | P/Q-Type Calcium Channel Antibody | 33980-4 |
| 2001772 | Glutamic Acid Decarboxylase Antibody | 56540-8 |
| 2004222 | NMDA Receptor Ab IgG CBA-IFA, Serum | 80221-5 |
| 2007962 | Purkinje Cell/Neuronal Nuclear IgG Scrn | 61177-2 |
| 2009453 | CASPR2 Ab IgG CBA-IFA Screen, Serum | 82979-6 |
| 2009457 | LGI1 Ab IgG CBA-IFA Screen, Serum | 82978-8 |
| 2013959 | CV2 Ab IgG CBA-IFA Screen, Serum | 72504-4 |
| 3001261 | AMPA Receptor Ab IgG CBA-IFA Scrn, Serum | 82733-7 |
| 3001271 | GABA-BR Ab IgG CBA-IFA Scrn, Ser | 93428-1 |
| 3002903 | SOX1 Antibody, IgG by Immunoblot, Serum | 82444-1 |
| 3004361 | DPPX Ab IgG CBA-IFA Screen, Serum | 94676-4 |
| 3006009 | GABA-AR Ab IgG CBA-IFA Screen, Serum | |
| 3006019 | IgLON5 Ab IgG CBA-IFA Screen, Serum | 96478-3 |
| 3006032 | ITPR1 Ab IgG CBA-IFA Screen, Serum | 96466-8 |
| 3006045 | mGluR1 Ab IgG CBA-IFA Screen, Serum | 93498-4 |
Aliases
- IgLON5
- rigidity
- AGNA
- AMPA
- AMPA-R
- Amphiphysin
- ANNA
- Anti-glial nuclear antibody
- Anti-neuronal nuclear antibody
- Ataxia
- Brainstem encephalitis
- CASPR2
- Chorea
- Contactin-associated protein-like-2
- CRMP-5
- CV2
- Dipeptidyl aminopeptidase-like protein 6
- DPPX
- Dyskinesias
- dystonia
- GABA-B
- GABA-BR
- GAD65
- Glutamic acid decarboxylase
- ITPR1
- Leucine-rich glioma inactivated protein-1
- LGI1
- metabotropic glutamate receptor 1
- mGluR1
- Movement disorder
- Myoclonus
- NMDA
- NMDA-R
- P/Q-type voltage-gated calcium channel
- P/Q-VGCC
- Parkinsonism
- PCA
- PCCA
- Purkinje cell cytoplasmic antibody
- VGCC
